---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009650"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:45:32.086268+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Coherus licenses toripalimab rights in Canada to Apotex for $6.25M upfront

## Summary
- Upfront payment of $6.25M USD; up to $51.5M CAD in regulatory and sales milestones.
- Apotex to pay low double-digit percentage of net sales; Coherus pays Junshi under existing collaboration.
- License term: 10 years after first commercial sale, with option to extend for another 10 years.
- Apotex may terminate for any reason after notice; agreement ends if Coherus-Junshi collaboration terminates.

## SEC filing metadata
- accession: 0001558370-24-009650
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024009650/0001558370-24-009650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024009650/chrs-20240627x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009650
- JSON: https://secwatch.observer/filing/0001558370-24-009650.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.